Junji Takada
Overview
Explore the profile of Junji Takada including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
174
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hayashi S, Ueno N, Murase A, Takada J
J Enzyme Inhib Med Chem
. 2014 Feb;
29(6):846-67.
PMID: 24517373
Because of the pivotal role of cyclooxygenase (COX) in the inflammatory processes, non-steroidal anti-inflammatory drugs (NSAIDs) that suppress COX activities have been used clinically for the treatment of inflammatory diseases/syndromes;...
2.
Hayashi S, Ueno N, Murase A, Nakagawa Y, Takada J
Eur J Med Chem
. 2012 Mar;
50:179-95.
PMID: 22373734
Cyclooxygenase (COX) is a key rate-limiting enzyme for prostaglandin (PG) production cascades in the human body. The mechanisms of both the anti-inflammation effects and the side-effects of traditional COX inhibitors...
3.
Hayashi S, Sumi Y, Ueno N, Murase A, Takada J
Biochem Pharmacol
. 2011 Jul;
82(7):755-68.
PMID: 21741371
Cyclooxygenase (COX) has been considered as a significant pharmacological target because of its pivotal roles in the prostaglandin biosynthesis and following cascades that lead to various (patho)physiological effects. Non-steroidal anti-inflammatory...
4.
Murase A, Nakao K, Takada J
Pharmacology
. 2008 Apr;
82(1):10-4.
PMID: 18408415
In order to characterize the receptor binding pharmacology of CJ-023,423, a potent and selective EP4 antagonist, we performed a radioligand receptor binding assay under various assay conditions. An acidic (pH...
5.
Murase A, Taniguchi Y, Tonai-Kachi H, Nakao K, Takada J
Life Sci
. 2007 Dec;
82(3-4):226-32.
PMID: 18155068
Activation of the prostaglandin E(2) (PGE(2)) EP(4) receptor, a G-protein-coupled receptor (GPCR), results in increases in intracellular cyclic AMP (cAMP) levels via stimulation of adenylate cyclase. Here we describe the...
6.
Murase A, Okumura T, Sakakibara A, Tonai-Kachi H, Nakao K, Takada J
Eur J Pharmacol
. 2007 Nov;
580(1-2):116-21.
PMID: 18031725
Recent study suggests that the proinflammatory and nociceptive effects of prostaglandin E(2) are mediated by prostanoid receptor subtype EP(4) and prostanoid EP(4) receptor may be a potential target for the...
7.
Nakao K, Murase A, Ohshiro H, Okumura T, Taniguchi K, Murata Y, et al.
J Pharmacol Exp Ther
. 2007 May;
322(2):686-94.
PMID: 17495127
The prostaglandin (PG) EP(4) receptor subtype is expressed by peripheral sensory neurons. Although a potential role of EP(4) receptor in pain has been suggested, a limited number of selective ligands...
8.
Lin C, Amaya F, Barrett L, Wang H, Takada J, Samad T, et al.
J Pharmacol Exp Ther
. 2006 Sep;
319(3):1096-103.
PMID: 16966471
Prostaglandin E(2) (PGE(2)) is both an inflammatory mediator released at the site of tissue inflammation and a neuromodulator that alters neuronal excitability and synaptic processing. The effects of PGE(2) are...